AG
IOVA icon

Algert Global’s Iovance Biotherapeutics IOVA Stock Holding History

Algert Global’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98M Buy
474,939
+182,010
+62% +$691K 0.02% 833
2026
Q1 		$1.03M Sell
292,929
-141,070
-33% -$451K 0.02% 860
2025
Q4 		$1.18M Buy
+433,999
New +$1M 0.02% 818
2025
Q2 		– Sell
-280,882
Closed -$935K – 1251
2025
Q1 		$935K Buy
280,882
+224,482
+398% +$1.16M 0.02% 779
2024
Q4 		$417K Buy
56,400
+2,330
+4% +$21.6K 0.01% 942
2024
Q3 		$508K Buy
54,070
+18,784
+53% +$178K 0.01% 893
2024
Q2 		$283K Sell
35,286
-3,492
-9% -$37.4K 0.01% 1142
2024
Q1 		$575K Sell
38,778
-81,310
-68% -$946K 0.02% 745
2023
Q4 		$976K Sell
120,088
-273,688
-70% -$1.43M 0.04% 625
2023
Q3 		$1.79M Buy
393,776
+41,470
+12% +$271K 0.08% 396
2023
Q2 		$2.48M Sell
352,306
-62,707
-15% -$449K 0.11% 326
2023
Q1 		$2.54M Buy
415,013
+23,620
+6% +$163K 0.12% 266
2022
Q4 		$2.5M Buy
391,393
+47,720
+14% +$373K 0.14% 225
2022
Q3 		$3.29M Buy
343,673
+178,868
+109% +$2.06M 0.2% 128
2022
Q2 		$1.82M Buy
164,805
+117,027
+245% +$1.53M 0.14% 222
2022
Q1 		$796K Buy
47,778
+11,403
+31% +$176K 0.05% 617
2021
Q4 		$694K Buy
36,375
+2,537
+7% +$55.9K 0.09% 415
2021
Q3 		$834K Buy
33,838
+20,388
+152% +$480K 0.11% 322
2021
Q2 		$350K Buy
+13,450
New +$350K 0.12% 248
2021
Q1 		– Sell
-11,621
Closed -$539K – 479
2020
Q4 		$539K Buy
+11,621
New +$461K 0.15% 213
2020
Q3 		– Sell
-30,757
Closed -$844K – 444
2020
Q2 		$844K Sell
30,757
-19,392
-39% -$638K 0.29% 125
2020
Q1 		$1.5M Buy
50,149
+26,138
+109% +$693K 0.63% 24
2019
Q4 		$665K Buy
+24,011
New +$546K 0.2% 170
2019
Q3 		– Sell
-13,080
Closed -$321K – 398
2019
Q2 		$321K Buy
+13,080
New +$197K 0.12% 215

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Algert Global's IOVA Position: Q2 2026 in Review

Algert Global increased its Iovance Biotherapeutics (IOVA) stake by 62% in Q2 2026, buying an estimated $691K and bringing the position to 474,939 shares worth $1.98M. The position accounts for 0.02% of the portfolio, ranked #833.

Algert Global first reported a position in IOVA in Q2 2019 and has held it in 24 quarters since. The position peaked at $3.29M in Q3 2022. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Algert Global held 474,939 shares of Iovance Biotherapeutics worth $1.98M as of Q2 2026.
  • Algert Global bought 182,010 Iovance Biotherapeutics shares in Q2 2026, an estimated $691K.
  • Iovance Biotherapeutics made up 0.02% of Algert Global's portfolio in Q2 2026, its #833 holding.
  • Algert Global first reported a position in Iovance Biotherapeutics in Q2 2019 and has held it in 24 quarters since.
  • Algert Global's Iovance Biotherapeutics position peaked at $3.29M in Q3 2022.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.